Chen Cui, Liu Xiumin, Xu Zhe, Xu Juan, Gong Lei, Wang Xiaobo
Qujing Medical College, Qujing, 655011, Yunnan Province, China.
School of Basic Medicine, Dali University, Dali, 671000, Yunnan, China.
Discov Oncol. 2025 Jul 23;16(1):1398. doi: 10.1007/s12672-025-03217-4.
Lung cancer is a highly aggressive malignancy that accounts for one of the greatest mortality rate in humans globally. Among various types of lung malignancies, lung adenocarcinoma (LUAD) stands out as the most common form. Sirtuins (SIRTs) are class III nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylases that comprise seven members (SIRT1-7). Sirtuins play a essentail role in various biological processes such as cellular differentiation, inflammation, apoptosis, metabolism, immune response, oxidative stress, mitochondrial homeostasis, and autophagy. Therefore, it is considered a potential therapeutic target for different kinds of pathologies including cancer, kidney diseases, and other conditions. While several reviews have been published on sirtuins and lung cancer, there remains a gap in the review regarding sirtuins specifically in LUAD. Herein, we not only elaborate on the roles of different sirtuins and their mechanisms in LUAD, but also discuss the potential application of sirtuins inhibitors and activators for LUAD therapy.
肺癌是一种侵袭性很强的恶性肿瘤，在全球人类中死亡率极高。在各类肺部恶性肿瘤中，肺腺癌（LUAD）是最常见的类型。沉默调节蛋白（SIRTs）是Ⅲ类烟酰胺腺嘌呤二核苷酸（NAD）依赖性组蛋白脱乙酰酶，由七个成员（SIRT1 - 7）组成。沉默调节蛋白在多种生物学过程中发挥着重要作用，如细胞分化、炎症、凋亡、代谢、免疫反应、氧化应激、线粒体稳态和自噬。因此，它被认为是包括癌症、肾脏疾病和其他病症在内的各种病理状态的潜在治疗靶点。虽然已经发表了几篇关于沉默调节蛋白与肺癌的综述，但关于沉默调节蛋白在肺腺癌中的综述仍存在空白。在此，我们不仅阐述了不同沉默调节蛋白在肺腺癌中的作用及其机制，还讨论了沉默调节蛋白抑制剂和激活剂在肺腺癌治疗中的潜在应用。
